Zileuton

Zileuton

SCHEMBL6601944

CC(c1cc2ccccc2s1)N(O)C(N)=O.CC(c1cc2ccccc2s1)N(O)C(N)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ALOX5

The experimentally established mechanism targets of Zileuton. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALOX5 known ✓ P09917 6/20 1.00
CYP1A2 P05177 2/20 1.00
PTGES O14684 1/20 1.00
LMNA P02545 1/20 1.00
LTA4H P09960 1/20 1.00
GAA P10253 1/20 1.00
ALOX15 P16050 1/20 1.00
ALOX12 P18054 1/20 1.00
ALOX5AP P20292 1/20 1.00
LOX P28300 1/20 1.00
EPHX2 P34913 1/20 1.00
PTGS2 P35354 1/20 1.00
LTB4R Q15722 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Zileuton SCHEMBL8876686 1.00 ALOX5 (1.00) ALOX5CYP1A2PTGESLMNALTA4H
Zileuton SCHEMBL4209 1.00 ALOX5 (1.00) ALOX5CYP1A2PTGESLMNALTA4H
Zileuton SCHEMBL18251470 1.00 ALOX5 (1.00) ALOX5CYP1A2PTGESLMNALTA4H
Zileuton SCHEMBL126156 1.00 ALOX5 (1.00) ALOX5CYP1A2PTGESLMNALTA4H
Zileuton SCHEMBL28562765 0.99 ALOX5 (0.97) ALOX5CYP1A2PTGESLMNALTA4H
Zileuton SCHEMBL9602587 0.99 ALOX5 (0.97) ALOX5CYP1A2PTGESLMNALTA4H
Zileuton SCHEMBL6335013 0.99 ALOX5 (0.97) ALOX5CYP1A2PTGESLMNALTA4H
Zileuton SCHEMBL20770716 0.95 ALOX5 (0.90) ALOX5CYP1A2PTGESLMNALTA4H
Methylamine SCHEMBL9601432 0.87 ALOX5 (0.77) ALOX5CYP1A2PTGESLMNALTA4H
SCHEMBL1444813 0.87 ALOX5 (0.76) ALOX5CYP1A2PTGESLMNALTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3675838-A1 LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS Puretecch LYT, Inc. (US) 2020-07-08 EP disclosed
WO-2019046491-A1 LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS ARIYA THERAPEUTICS, INC. (US) 2019-03-07 WO disclosed
EP-3094332-A1 CARBONYL ERASTIN ANALOGS AND THEIR USE The Trustees of Columbia University in the City of New York (US) 2016-11-23 EP disclosed
WO-2015109009-A1 CARBONYL ERASTIN ANALOGS AND THEIR USE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2015-07-23 WO disclosed
WO-2014011973-A2 QUINAZOLINONE-BASED ONCOGENIC-RAS-SELECTIVE LETHAL COMPOUNDS AND THEIR USE THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) 2014-01-16 WO disclosed
EP-1373258-A1 ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES Pfizer Products Inc. (US) 2004-01-02 EP disclosed
EP-1355884-A1 NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES Pfizer Products Inc. (US) 2003-10-29 EP disclosed
EP-1355907-A1 THIAZOLYL-, OXAZOLYL-, PYRROLYL-, AND IMIDAZOLYL-ACID AMIDE DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES Pfizer Products Inc. (US) 2003-10-29 EP disclosed
EP-1252158-A1 NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES Pfizer Products Inc. (US) 2002-10-30 EP disclosed
EP-1252157-A1 PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES Pfizer Products Inc. (US) 2002-10-30 EP disclosed
WO-2002060896-A1 ETHER DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES PFIZER PRODUCTS INC. (US) 2002-08-08 WO disclosed
WO-2002060898-A1 THIAZOLYL-, OXAZOLYL-, PYRROLYL-, AND IMIDAZOLYL-ACID AMIDE DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES PFIZER PRODUCTS INC. (US) 2002-08-08 WO disclosed
WO-2002060875-A1 NICOTINAMIDE BIARYL DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES PFIZER PRODUCTS INC. (US) 2002-08-08 WO disclosed
US-6355434-B1 DETERMINING IF ASTHMA PATIENTS HAVE DIFFERENCES IN 5-LIPOXYGENASE GENE REGULATORY SEQUENCE, COMPARED TO NORMAL CONTROLS WITHOUT ASTHMA; DETECTING VARIANCE IN THE GENE, IDENTIFIES PATIENTS FOR EFFECTIVE TREATMENT WITH INHIBITORS BRIGHAM & WOMEN'S HOSPITAL 2002-03-12 US disclosed
WO-2001057036-A1 NICOTINAMIDE BENZOFUSED-HETEROCYCLYL DERIVATIVES USEFUL AS SELECTIVE INHIBITORS OF PDE4 ISOZYMES PFIZER PRODUCTS INC. (US) 2001-08-09 WO disclosed
WO-2001057025-A1 PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES PFIZER PRODUCTS INC. (US) 2001-08-09 WO disclosed
US-6090547-A BY DETECTING ELEVATED 5-LIPOXYGENASE EXPRESSION IN THE PATIENT BRIGHAM & WOMEN'S HOSPITAL (US) 2000-07-18 US disclosed
US-RE36115-E Process for producing amine-boranes BOULDER SCIENTIFIC COMPANY (US) 1999-02-23 US disclosed
EP-0896633-A2 5-LIPOXYGENASE GENE POLYMORPHISMS AND THEIR USE IN CLASSIFYING PATIENTS BRIGHAM AND WOMEN'S HOSPITAL (US) 1999-02-17 EP disclosed
WO-1997042347-A2 5-LIPOXYGENASE GENE POLYMORPHISMS AND THEIR USE IN CLASSIFYING PATIENTS BRIGHAM AND WOMEN'S HOSPITAL (US) 1997-11-13 WO disclosed